Outcomes of Transformation to Acute Myeloid Leukemia after Hypomethylating Agent Therapy in Patients With Myelodysplastic Syndromes

被引：0
|
作者：
Kim, Kunhwa [1 ]
Ong, Faustine [1 ]
Li, Ziyi [2 ]
Shamanna, Rashmi Kanagal [3 ]
Bravo, Guillermo Montalban [1 ]
Kadia, Tapan [1 ]
Jabbour, Elias [1 ]
Pemmaraju, Naveen [1 ]
Hammond, Danielle [1 ]
Short, Nicholas [1 ]
Ravandi, Farhad [1 ]
Alvarado, Yesid [1 ]
Pierce, Sherry [1 ]
Dong, Xiao Qin [1 ]
Kantarjian, Hagop [1 ]
Garcia-Manero, Guillermo [1 ]
Chien, Kelly [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷
关键词：
MDS; hypomethylating agent; hypomethylating agent failure; AML;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MDS-431
引用
收藏
页码：S313 / S314
页数：2
相关论文
共 50 条
  • [1] Optimizing DNA hypomethylating therapy in acute myeloid leukemia and myelodysplastic syndromes
    Straube, Jasmin
    Lane, Steven W.
    Vu, Therese
    [J]. BIOESSAYS, 2021, 43 (10)
  • [2] Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia
    Ball, Brian
    Komrokji, Rami S.
    Ades, Lionel
    Sekeres, Mikkael A.
    DeZern, Amy E.
    Pleyer, Lisa
    Vey, Norbert
    Almeida, Antonio
    Germing, Ulrich
    Cluzeau, Thomas
    Platzbecker, Uwe
    Gore, Steven D.
    Fenaux, Pierre
    Prebet, Thomas
    [J]. BLOOD ADVANCES, 2018, 2 (16) : 2063 - 2071
  • [3] Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia
    Sorrentino, Vincent G.
    Thota, Srijan
    Gonzalez, Edward A.
    Rameshwar, Pranela
    Chang, Victor T.
    Etchegaray, Jean-Pierre
    [J]. PHARMACEUTICALS, 2021, 14 (07)
  • [4] Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes and Myeloid Leukemia
    Szmigielska-Kaplon, Anna
    Robak, Tadeusz
    [J]. CURRENT CANCER DRUG TARGETS, 2011, 11 (07) : 837 - 848
  • [5] Practical Recommendations for Hypomethylating Agent Therapy of Patients With Myelodysplastic Syndromes
    Steensma, David P.
    Stone, Richard M.
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2010, 24 (02) : 389 - +
  • [6] Efficacy and Safety of Bemcentinib in Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Failing Hypomethylating Agents
    Kubasch, Anne Sophie
    Peterlin, Pierre
    Cluzeau, Thomas
    Gotze, Katharina S.
    Sockel, Katja
    Teipel, Raphael
    Jentzsch, Madlen
    Kayser, Sabine
    Attalah, Habiba
    Chermat, Fatiha
    Gloaguen, Silke
    Jersemann, Katja
    Schipp, Dorothea
    Giagounidis, Aristoteles
    McPherson, Stuart
    Tirado-Gonzalez, Irene
    van de Loosdrecht, Arjan
    Fenaux, Pierre
    Platzbecker, Uwe
    Medyouf, Hind
    Ades, Lionel
    [J]. BLOOD, 2020, 136
  • [7] Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes
    Wong, Kah Keng
    Hassan, Rosline
    Yaacob, Nik Soriani
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [8] Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes
    Hong Wang
    Yan Li
    Na Lv
    Yonghui Li
    Lili Wang
    Li Yu
    [J]. Annals of Hematology, 2018, 97 : 2025 - 2038
  • [9] The path to approval for oral hypomethylating agents in acute myeloid leukemia and myelodysplastic syndromes
    Kipp, David
    H Wei, Andrew
    [J]. FUTURE ONCOLOGY, 2021, 17 (20) : 2563 - 2571
  • [10] Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes
    Wang, Hong
    Li, Yan
    Lv, Na
    Li, Yonghui
    Wang, Lili
    Yu, Li
    [J]. ANNALS OF HEMATOLOGY, 2018, 97 (11) : 2025 - 2038
12345